From GlobeNewswire: 2025-06-09 07:45:00

BioRestorative Therapies, Inc. will unveil new safety and efficacy data from 30 patients in an ongoing Phase 2 trial on June 13, 2025, at ISSCR 2025. The data will be presented by Francisco Silva, VP of R&D, and highlight positive signals for safety and functional improvement in treating chronic lumbar disc disease with BRTX-100. This therapy targets damaged spinal discs using autologous mesenchymal stem cells. The presentation will focus on patient-reported pain and function metrics, as well as safety endpoints. ISSCR 2025 is a global stem cell research event, attracting nearly 4,000 leaders from academia, biotech, and pharma, providing a platform for BioRestorative to share its latest advancements.



Read more at GlobeNewswire: BioRestorative to Present Major Update on Promising